SEC Form 10-Q filed by VolitionRX Limited
$VNRX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2025 | $2.50 | Buy | H.C. Wainwright |
| 2/1/2023 | Buy → Hold | The Benchmark Company | |
| 2/17/2022 | $8.00 → $7.00 | Overweight | Cantor Fitzgerald |
| 11/16/2021 | $10.00 → $9.00 | Buy | Aegis Capital |
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50
The Benchmark Company downgraded VolitionRx from Buy to Hold
Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously
8-K - VOLITIONRX LTD (0000093314) (Filer)
8-K - VOLITIONRX LTD (0000093314) (Filer)
10-Q - VOLITIONRX LTD (0000093314) (Filer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement (the "Amended Agreement") with Lind Global Asset Management XII LLC (the "Investor"), an investment fund managed by The Lind Partners, a New York-based institutional fund manager. Under the Amended Agreement, the Company will receive aggregate gross proceeds of $2,000,000 from the Investor in exchange for the issuance to the Investor of a senior secured convertible promissory note in the principal amount of $2,400,000 (the "2026 Note"), and a five-year co
Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas2 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine. Frédéric Wuilque, VP
HENDERSON, Nev., Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025. Review of the Year by Cameron Reynolds, Group Chief Executive Officer As 2025 draws to a close, I would like to take this opportunity to look back on the year's key milestones and look to the opportunities ahead. Before diving into the detail, I would like to take a moment to reflect on our founding mission. We set out over fifteen years ago to help save lives and improve outcomes for millions of patients worldwide, and I could not be prouder of the progress we are making towards that goal. In this fourth quarter we not only rece
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)
HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a
HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development
HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses
Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter of 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Third Quarter 2025 Earnings and Business Update Conference Call Date: Friday, November 14, 2025Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800
Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call Date: Friday, August 15, 2025Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 34
Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025. Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum